Wells Fargo
NRXP icon

Wells Fargo’s NRX Pharmaceuticals NRXP Stock Holding History

Wells Fargo’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.18K Sell
2,000
-350
-15% -$1.16K ﹤0.01% 6122
2026
Q1 		$5.01K Buy
2,350
+350
+18% +$707 ﹤0.01% 6118
2025
Q4 		$5.42K Hold
2,000
– – ﹤0.01% 6079
2025
Q3 		$6.6K Hold
2,000
– – ﹤0.01% 6025
2025
Q2 		$6.52K Sell
2,000
-160
-7% -$401 ﹤0.01% 6040
2025
Q1 		$4.43K Hold
2,160
– – ﹤0.01% 6044
2024
Q4 		$4.75K Sell
2,160
-500
-19% -$672 ﹤0.01% 6072
2024
Q3 		$4.5K Buy
2,660
+1,160
+77% +$2.34K ﹤0.01% 5935
2024
Q2 		$3.66K Buy
1,500
+957
+176% +$3.4K ﹤0.01% 5924
2024
Q1 		$2.56K Buy
543
+1
+0.2% +$5 ﹤0.01% 5989
2023
Q4 		$2.49K Buy
542
+4
+0.7% +$13 ﹤0.01% 6067
2023
Q3 		$1.4K Buy
538
+4
+0.7% +$13 ﹤0.01% 6149
2023
Q2 		$2.58K Buy
534
+3
+0.6% +$18 ﹤0.01% 6177
2023
Q1 		$3.5K Buy
531
+1
+0.2% +$10 ﹤0.01% 6130
2022
Q4 		$5.89K Buy
530
+1
+0.2% +$10 ﹤0.01% 5723
2022
Q3 		$4K Buy
529
+6
+1% +$40 ﹤0.01% 5981
2022
Q2 		$3K Buy
523
+23
+5% +$302 ﹤0.01% 6201
2022
Q1 		$12K Hold
500
– – ﹤0.01% 6206
2021
Q4 		$24K Hold
500
– – ﹤0.01% 6274
2021
Q3 		$46K Buy
+500
New +$65K ﹤0.01% 5653

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wells Fargo's NRXP Position: Q2 2026 in Review

Wells Fargo reduced its NRX Pharmaceuticals (NRXP) stake by 15% in Q2 2026, selling an estimated $1.16K and leaving 2,000 shares worth $8.18K. The position accounts for ﹤0.01% of the portfolio, ranked #6122.

Wells Fargo first reported a position in NRXP in Q3 2021 and has held it in 20 quarters since. The position peaked at $46K in Q3 2021. 46 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • Wells Fargo held 2,000 shares of NRX Pharmaceuticals worth $8.18K as of Q2 2026.
  • Wells Fargo sold 350 NRX Pharmaceuticals shares in Q2 2026, an estimated $1.16K.
  • NRX Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6122 holding.
  • Wells Fargo first reported a position in NRX Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • Wells Fargo's NRX Pharmaceuticals position peaked at $46K in Q3 2021.
  • 46 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.